Gilead's remdesivir to be used to treat coronavirus patients in S. Korea
SEOUL, March 3 (Yonhap) -- Glead Sciences' experimental antiviral drug remdesivir is expected to be used to treat patients infected with the novel coronavirus in South Korea as part of a trial, drug industry sources said Tuesday.
Remdesivir, an investigational medication developed by U.S. pharmaceutical giant Gilead Sciences Inc., was previously tested against the Ebola virus. The drug has shown efficacy in COVID-19 patients in other countries on a trial basis as there is no specific treatment.
The sources said Gilead Sciences has been granted approval from local drug authorities to begin phase-three clinical trials of remdesivir for the treatment of COVID-19 in adult patients.
The approval by the Ministry of Food and Drug Safety came only four days after the application.
"Experimental drugs under clinical trial are sometimes granted approval for usage in cases where diseases are life-threatening and there is no other treatment option," a ministry official said on condition of anonymity.
Remdesivir, currently under clinical trials in several countries, such as China, the epicenter of the outbreak, the United States and Japan, has not been fully approved by any country.
The ministry also allowed a locally-developed antiviral drug called Virus Suppressing Factor (VSF) to treat COVID-19 patients at the request of Seoul National University Hospital.
COVID-19 patients will be administered with a therapy called HzVSFv13, an injection-type of VSF developed by mid-sized bio firm ImmuneMed.
So far, most COVID-19 patients have been given treatments to relieve their symptoms while severe patients were given a combination of flu medicine and Kaletra, an anti-retroviral medication that was developed by global pharmaceutical firm AbbVie Inc. and is used to treat HIV.
The public health agency earlier announced a proposed protocol, which advises doctors to administer Kaletra twice a day to elderly patients and those who show severe symptoms of the coronavirus.
The 374 new cases, which were identified over the past 16 hours on Tuesday, brought the nation's total number of infections to 5,186. Tuesday's additional cases followed 600 new cases as of end-Monday, the nation's sharpest daily spikes of 1,062 as of end-Sunday and 813 as of end-Saturday.
khj@yna.co.kr
(END)
-
S. Korea to resume issuing short-term travel visas, e-visas next month
-
Ateez to drop new Japanese EP next week
-
(2nd LD) BTS wins three Billboard Music Awards, marking 6th year to win an award
-
Crypto investor probed over allegedly visiting house of Terraform's CEO
-
(2nd LD) N. Korea still unresponsive to S. Korea's outreach for talks on COVID-19: official
-
S. Korea to resume issuing short-term travel visas, e-visas next month
-
(5th LD) Yoon, Biden agree to expand joint military exercises to cope with N.K. threats
-
(LEAD) Yoon, PPP lawmakers travel to Gwangju en masse to commemorate 1980 democracy uprising
-
(LEAD) At least 8 injured in S-Oil refinery explosion in Ulsan: firefighters
-
(LEAD) Biden set to arrive in S. Korea for first summit with Yoon
-
Chinese people purchase nearly 7,000 buildings in S. Korea in 2021
-
Biden says he and Yoon 'married up'
-
U.S. not considering adding S. Korea to Quad: official
-
With historic Golden Boot, Son Heung-min cements case as greatest S. Korean footballer ever
-
(2nd LD) Yoon, Biden tout alliance during visit to Air Force operations center